Trump fast-tracks psychedelic drugs for mental healthcare use
The Trump administration signaled it will accelerate the FDA review process for psychedelic compounds like psilocybin and MDMA, targeting depression, PTSD and addiction treatment. The shift could broaden treatment options for veterans while creating opportunities for emerging biotech firms.
CNBC Top NewsAccording to CNBC, the Trump administration is showing explicit political backing for accelerating the regulatory pathway for psychedelic compounds previously classified as controlled substances. Health Secretary Robert F. Kennedy Jr and FDA Commissioner Marty Makary cited long-running clinical research into psilocybin and MDMA-based protocols for veteran mental health and treatment-resistant psychiatric conditions.
The move could lift shares of sector-representative firms such as ATAI Life Sciences, Compass Pathways and MindMed, although FDA officials emphasised the agency has not relaxed efficacy and safety standards. Researchers including Dr Caitlin Davis at Massachusetts General Brigham and Prof Roland Griffiths at Johns Hopkins flagged risks tied to use outside supervised clinical settings.
Washington's approach is drawing global attention as the European Medicines Agency launched a similar review cycle in 2025. Sector analysts cite forecasts that the US market could exceed $8 billion by 2030; the regulatory framework, insurance reimbursement and psychiatrist certification questions should clarify in coming months. This piece is not investment or medical advice.
More from North America
Oklahoma minimum wage vote seen as 2026 inflation barometer
Voters in deeply Republican Oklahoma will weigh a ballot measure to double the state minimum wage in one of the 2026 election cycle's key votes. The outcome could become an early signal of how parties read the inflation outlook and shifting voter mood.
UAE says OPEC exit was a strategic economic move, not political
The United Arab Emirates said its decision to leave OPEC was a strategic economic choice rather than a political one. Officials told CNBC the move lets the country deploy spare production capacity freely and align output with its energy diversification plans.
BlackRock weighs $5-10 billion investment in SpaceX IPO
BlackRock is in talks to commit between $5 billion and $10 billion to SpaceX's upcoming initial public offering, The Information reported. The investment, if completed, would mark one of the largest single-firm commitments to a US listing in years.